Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Group 1 - AnaptysBio, Inc. (ANAB) has shown strong year-to-date performance, returning 22%, significantly outperforming the Medical sector average of 5% [4] - The Zacks Consensus Estimate for ANAB's full-year earnings has increased by 15.7% in the past quarter, indicating improved analyst sentiment and earnings outlook [4] - AnaptysBio, Inc. is ranked 2 (Buy) in the Zacks Rank, which highlights stocks with characteristics likely to outperform the market in the near term [3] Group 2 - AnaptysBio, Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 510 companies and is currently ranked 66 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has an average year-to-date return of 12.3%, indicating that ANAB is performing better than its industry peers [6] - Another outperforming stock in the Medical sector is AtriCure (ATRC), which has returned 38.6% year-to-date and also holds a Zacks Rank of 2 (Buy) [5][7]